Royalty Pharma Plc (RPRX NASDAQ) stock market data APIs
$36.085
0.13(0.4%)
as of July 11, 2025
Try our APIs with
free plan!
Royalty Pharma Plc Financial Data Overview
Price chart is built with
Anychart
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Prev. Close
36.085
Open
36.2174
High
36.2174
Low
35.8563
52 wk Range
23.7325-36.56
Market Cap
20 308 M
P/E Ratio
14.749
Shares Outstanding
421 M
Revenue
2 264 M
EPS
1.06
Dividends (Yield)
0.0244
Beta
0.474
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Royalty Pharma Plc data using free add-ons & libraries
Get Royalty Pharma Plc Fundamental Data
Royalty Pharma Plc Fundamental data includes:
- Net Revenue: 2 264 M
- EBITDA: 1 498 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: 0.95
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Royalty Pharma Plc News
New
Investors in Royalty Pharma (NASDAQ:RPRX) have seen respectable returns of 40% over the past year
Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly boost your returns by picking above-average stocks. For example, the Royalty Phar...
5 Revealing Analyst Questions From Royalty Pharma’s Q1 Earnings Call
Royalty Pharma’s first quarter reflected a stable performance, with revenue in line with Wall Street expectations and non-GAAP profitability exceeding consensus. Management highlighted double-digit ...
2 Surging Stocks to Research Further and 1 to Be Wary Of
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial p...
Revolution Medicines dips 5%, gets $2B flexible funding
* A late-stage clinical oncology company, Revolution Medicines (NASDAQ:RVMD [https://seekingalpha.com/symbol/RVMD]) partnered with [https://seekingalpha.com/pr/20145272-revolution-medicines-enters-i...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
